|
|
|
| Obesity Tx End-Around With Skye Bioscience's Punit Dhillon | While the trend toward CB1 inhibition for obesity took a small hit with the release of Novo Nordisk's small molecule oral cannabinoid receptor (CB1) inverse agonist monlunabant, Skye Bioscience CEO Punit Dhillon is confident that their antibody-based approach to CB1 inhibition will make a moot point of the neuropsychiatric side effects that put a damper on Novo's data. On the Business of Biotech, we're digging into the uber-hot business of weight loss therapeutics. |
|
|
|
|
Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, glaucoma, and Fragile X syndrome. |
|
|
|
|
| Inspiring A New Era Of Patient-Centric Medicines | Patients are more empowered, making it essential to promote better adherence, improve medical benefits, and bolster market perception. See the technologies enabling this shift toward patient-centricity. |
|
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|
